The Companion Diagnostics (CDX) Market Forecast 2016-2026

15 Apr, 2016, 09:00 ET from Visiongain

LONDON, April 15, 2016 /PRNewswire/ --

Leading Companies, Trends and Developments in the Growing Theranostics Market

What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 192-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

The report also includes will find revenue forecasts to 2026 for the following submarkets in the companion diagnostics market:
• Theranostics
• Other Companion Diagnostics

Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.

The report also includes will find revenue forecasts to 2026 for the following national and regional markets for companion diagnostics:
• US
Germany
France
Italy
Spain
• UK
Japan
China
India
Russia
Brazil
South Korea

The report provides detailed profiles of key companies operating within the companion diagnostics market:
• F. Hoffmann-La Roche Ltd
• Qiagen N.V.
• Abbott Laboratories
• Agilent Technologies
• Myriad Genetics
• bioMerieux
• Thermo Fisher Scientific

Leading companies and potential for market growth
Overall revenue for the Companion Diagnostics market will reach $10.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of 7 leading companies, including these:
• F. Hoffmann-La Roche Ltd
• Qiagen N.V.
• Abbott Laboratories
• Agilent Technologies
• Myriad Genetics
• bioMerieux
• Thermo Fisher Scientific

A company profile gives you the following information where available:
• Discussion of a company's activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 5 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the companion diagnostics industry?
Our new report discusses issues and events affecting the companion diagnostics market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Changing regulatory landscape challenging new entrants and major market players alike
• Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Companion Diagnostics: Market Forecast 2016-2026 report helps you
In summary, our 192-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Companion Diagnostics market - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket - discover prospects for leading companion diagnostics products in the following areas: theranostics and other companion diagnostics.
• Revenue forecasts to 2026 for twelve leading national markets - US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea
• Assessment of 7 leading companies - analysis of products, revenue, mergers & acquisitions, sales by region and products
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the companion diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.


Companies Mentioned in the Report
20/20 Gene Systems
Abbott Laboratories
Abbott Molecular
AbbVie
Advanced Scientifics
Affymetrix
Agilent Technologies
Alere
Alfa Aesar
Almac
Ambry Genetics
Amgen
Arca Biopharma
Argene
Ariosa Diagnostics
Arno
Astellas Pharma
AstraZeneca
Astute Medical
Asuragen
AviaraDx
Bayer
Bina Technologies,
Biocartis
Biofire Diagnostics
bioMerieux
Biomonitor
Boehringer Ingleheim
Bristol Myers-Squi
CAPP Medical
Caprion Proteomics
Caris Life Sciences
Celera (Quest Diagnostics)
Celgene
Cepheid
Clarient
Clinical Regerence Laboratory
Clovis Oncology
CompanDx
Crescendo Bioscience
Curidium Medica
Dako (Agilent Technologies)
DiagnoCUr
Dutalys
Dx Assays
Eli Lilly
Endocyte
Epizyme
Exosome Diagnostics
F. Hoffmann-La Roche Ltd.
Ferring Pharmaceuticals
Flagship Biosciences
FlowMetric Diagnostics
Foundation Medicine
GE
Genentech
GENEWEAVE Biosciences, Inc.
Genfit
Genia Technologies, Inc.
Genmab
Genmark Diagnostics
Gilead Sciences
GlaxoSmithKline
Hexie Health
HistologiX
Idera Pharmaceutical
IGEN International
Ilumina
ImmunoGen
Incyte
InDex Pharmaceuticals
Institut Merieux
Inverness Medical Innovations
Invivoscribe Technologies
Ipsen
Ipsogen
IQuum, Inc.
Johnson Matthey Plc
Kapa Biosystems
Keysight Technologies
Kimball Genetics
Kunlun Health Insurance
Lab 21
Lab Corp.
Leica Biosystems
Leica Microsystems
Life Technologies
Luminex
MedImmune
Merck & Co.
Merck KGaA
Merck Serono
Molecular MD
Myriad Genetics
Nanosphere
Nanostring
NIH
Novartis
Origin Technologies Corp.
OSI Pharmaceuticals
Oxford BioTherapeutics
Pfizer
PICC Health Insurance
Ping An Insurance Group
PrimeraDx
Prionics
Progenika Biopharma
Prometheus
Protagen
Qiagen N.V.
Quest Diagnostics
Quintiles Transnational Corporation
Randox Pharma Services
RAS Lifesciences Pvt. Ltd
RiboMed Biotechnologies
Saladax Biomedical
Santaris Pharma A/S
Seragon Pharmaceuticals
Siemens Healthcare
Signature Diagnostics AG
Sirius Genomics
Synthon Biopharmaceuticals
Sysmex Inostics
Takeda Pharmaceuticals
Target Discovery
TcLand Expression
TESARO
Theranostics
Thermo Fisher Scientific
Third Wave Technologies
TIB MOLBiol
Tragara Pharmaceuticals
Transgenomic
TrimGEn Crorporation
Trophos
Unilabs
Ventana Medical Systems (Roche)
Weisenthal Cancer Group

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100

Or click on https://www.visiongain.com/Report/1614/The-Companion-Diagnostics-%28CDx%29-Market-Forecast-2016-2026

 

SOURCE Visiongain